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Leipzig and Munich, Germany; Aalst, Belgium; Massy, France; and London, United KingdomObjectives This study sought to report the ﬁnal 5 years follow-up of the landmark LEADERS (Limus
Eluted From A Durable Versus ERodable Stent Coating) trial.
Background The LEADERS trial is the ﬁrst randomized study to evaluate biodegradable polymer–
based drug-eluting stents (DES) against durable polymer DES.
Methods The LEADERS trial was a 10-center, assessor-blind, noninferiority, “all-comers” trial
(N ¼ 1,707). All patients were centrally randomized to treatment with either biodegradable polymer
biolimus-eluting stents (BES) (n ¼ 857) or durable polymer sirolimus-eluting stents (SES) (n ¼ 850). The
primary endpoint was a composite of cardiac death, myocardial infarction (MI), or clinically indicated
target vessel revascularization within 9 months. Secondary endpoints included extending the primary
endpoint to 5 years and stent thrombosis (ST) (Academic Research Consortium deﬁnition). Analysis
was by intention to treat.
Results At 5 years, the BES was noninferior to SES for the primary endpoint (186 [22.3%] vs. 216 [26.1%],
rate ratio [RR]: 0.83 [95% conﬁdence interval (CI): 0.68 to 1.02], p for noninferiority <0.0001, p for
superiority ¼ 0.069). The BES was associated with a signiﬁcant reduction in the more comprehensive
patient-orientated composite endpoint of all-cause death, any MI, and all-cause revascularization (297
[35.1%] vs. 339 [40.4%], RR: 0.84 [95% CI: 0.71 to 0.98], p for superiority¼ 0.023). A signiﬁcant reduction in
very late deﬁnite ST from1 to 5 years was evident with the BES (n¼ 5 [0.7%] vs. n¼ 19 [2.5%], RR: 0.26 [95%
CI: 0.10 to0.68], p¼ 0.003), corresponding to a signiﬁcant reduction in ST-associated clinical events (primary
endpoint) over the sametimeperiod (n¼ 3of749vs. n¼ 14of738, RR: 0.20 [95%CI: 0.06 to0.71], p¼ 0.005).
Conclusions The safety beneﬁt of the biodegradable polymer BES, compared with the durable polymer
SES, was related to a signiﬁcant reduction in very late ST (>1 year) and associated composite clinical
outcomes. (Limus Eluted From A Durable Versus ERodable Stent Coating [LEADERS] trial; NCT00389220)
(J Am Coll Cardiol Intv 2013;6:777–89) ª 2013 by the American College of Cardiology Foundation
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778Within the last decade, percutaneous coronary intervention in this study, applies the antiproliferative biolimus A-9
(PCI) with ﬁrst- and newer-generation drug-eluting stents
(DES) has emerged as the standard of care for patients with less
complex coronary artery disease (1–4). One of the major caveats
of ﬁrst-generation DES has been related to patient safety.
Namely, the durable polymer carrier of ﬁrst-generation DES,
vital for controlling the release of an antiproliferative agent
to limit the vessel injury response after device implantation
(5,6), has been implicated as leading to device failure: ﬁrst,
through the polymer carrier causing a persistent inﬂammatory
response, with resultant delayed and incomplete endotheliali-
zation, positive remodeling with late acquired malapposition,
and risk of stent thrombosis (ST) (7–12); second, as aFrom the *Thoraxcenter, Erasmus Un
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BES = biolimus-eluting stent(s)
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revascularization“late catch-up” phenomenon in
neointimal proliferation, with
a resultant risk of late restenosis
secondary to an ongoing inﬂam-
matory response to the perma-
nent polymer (13,14); and
third, through accelerating neo-
atherosclerosis, to which DES
have been linked, and the
subsequent risk of late device
failure (restenosis or thrombosis)
compared with bare-metal stents
(BMS) (15,16).
Newer-generation biodegrad-
able polymerDESwere designed
to overcome many of the limita-
tions of ﬁrst-generation DES
by allowing for a more biocom-
patible polymer to control the
delivery of predominantly limus-
based antiproliferative agents,
which were often abluminally
coated, to theoretically limit the
delay in arterial healing (17). The
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and consulting fees from Cordis, AstraZeneca,agentdimmersed at a concentration of 15.6 mg/mm into
a biodegradable polylactic acid biocompatible polymerdto the
abluminal stent surface of a ﬂexible stainless-steel stent plat-
form. The stent platform has a Quadrature Link design with
a strut thickness of 120 mm. The biolimus A-9 agent is
a semisynthetic sirolimus analogue with 10 higher lip-
ophilicity and similar potency as sirolimus, and is rapidly
absorbed in tissues, where it reversibly inhibits growth factor–
stimulated cell proliferation by forming a complex with the
cytoplasmic proteins that inhibit the cell cycle between the G0
andG1phases. BiolimusA-9 is co-releasedwith polylactic acid
and completely dissolves into carbon dioxide and water after
a 6- to 9-month period (18).
The goal of the LEADERS (Limus Eluted From A
Durable Versus ERodable Stent Coating) trial was to
directly compare the biodegradable polymer BES platform
against the durable polymer sirolimus-eluting stent (SES)
platform, in a prospective, multicenter, randomized, con-
trolled, noninferiority “all-comers” trial. The primary end-
point of the LEADERS trial at 9 months has conﬁrmed
the noninferiority of the biodegradable polymer BES to the
durable polymer SES (19,20). This analysis presents the
ﬁnal 5-year results of the LEADERS trial.
Methods
Study design and patients. The design and methods for the
LEADERS trial (NCT00389220) have been previously
described and are summarized in the following text (19–21). In
brief, thiswas a prospective,multicenter, randomized, assessor-
blind, noninferiority trial, conducted in 10 European inter-
ventional cardiology sites (N ¼ 1,707). Reﬂecting real-world
practice, the study was all-comers in design, with minimal
exclusion criteria. Patients had to be 18 years old, with
symptomatic coronary artery disease (including chronic stable
angina, silent ischemia, and acute coronary syndrome [ACS]),
have the presence of 1 or more coronary artery stenoses
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randomized
Figure 1. The LEADERS 5-Year Trial Proﬁle
A total of 1,707 patients were enrolled and randomized to biodegradable polymer BES (n ¼857) or durable polymer SES (n ¼850). *No reliable data for patients
assessed for eligibility; ynumber of patients does not add up because of multiple lesions treated per patient; z1 patient allocated to biodegradable polymer biolimus-
eluting stent (BES), and 2 allocated to durable polymer sirolimus-eluting stent (SES), received neither angiography nor percutaneous coronary intervention; these
patients were assumed to have 1 index lesion. BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); LEADERS ¼ Limus Eluted From A Durable Versus ERodable Stent
Coating.
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779(reference vessel diameter ranging from 2.25 to 3.5 mm that
could be covered with 1 or multiple DES). Exclusion criteria
were limited, and included pregnancy; known intolerance to
aspirin, clopidogrel, heparin, stainless steel, sirolimus, bio-
limus, or contrast material; an inability to provide informed
consent; patient participation in another trial before reaching
the primary endpoint; or planned surgery within 6 months of
PCI unless dual antiplatelet therapy was maintained
throughout the perisurgical period.
After coronary angiography, checking of eligibility criteria,
and the obtaining of written informed consent, patients
were centrally randomized on a 1:1 basis to either the
biodegradable polymer BES (BioMatrix Flex, Biosensors,
Newport Beach, California) or the durable polymer ﬁrst-
generation SES (Cypher SELECT, Cordis, Miami Lakes,
Florida) using an interactive voice response system. The study
was conducted in accordance with the principles of the
Declaration of Helsinki, and all site-speciﬁc institutionalreview boards and applicable regulatory agencies approved
the study protocol before study initiation. Procedures were
performed according to routine local clinical practice using
standard techniques. No limitation was placed on the
number of treated lesions, number of vessels, or lesion length
according to the randomization group. Patients were
mandated to receive the same stent type for all lesions.
Dual antiplatelet therapy was mandated for 12 months
post-device implantation. The SYNTAX score (22–25) was
calculated by an independent core laboratory (Cardialysis BV,
Rotterdam, the Netherlands), blinded to the treatment
assignment.
Study endpoints. The primary endpoint of the LEADERS
trial was major adverse cardiac events (MACE), deﬁned as
the composite of cardiac death, myocardial infarction (MI)
(Q-wave and non–Q-wave), or clinically indicated target
vessel revascularization (TVR) within 9 months. Secondary
endpoints included MACE, its individual components, and
Table 1. Comparisons of Antiplatelet Usage Between the Biodegradable
Polymer BES and Durable Polymer SES up to 5 Years
Biodegradable
Polymer BES
Durable
Polymer SES p Value
Aspirin
At 1 yr 783/810 (97) 769/801 (96) 0.48
At 2 yrs 751/790 (95) 733/777 (94) 0.52
At 3 yrs 714/758 (94) 710/748 (95) 0.54
At 4 yrs 692/748 (93) 681/735 (93) 0.92
At 5 yrs 664/724 (92) 644/696 (93) 0.57
Clopidogrel or ticlopidine
At 1 yr 548/810 (68) 533/801 (67) 0.64
At 2 yrs 182/790 (23) 189/777 (24) 0.55
At 3 yrs 146/758 (19) 152/749 (20) 0.62
At 4 yrs 118/748 (16) 135/735 (18) 0.19
At 5 yrs 115/724 (16) 118/696 (17) 0.59
Dual antiplatelet therapy
At 1 yr 530/810 (65) 511/801 (64) 0.49
At 2 yrs 168/790 (21) 168/777 (22) 0.86
At 3 yrs 123/758 (16) 132/748 (18) 0.46
At 4 yrs 95/748 (13) 111/735 (15) 0.18
At 5 yrs 92/724 (13) 97/696 (14) 0.50
Values are n/total n (%).
BMS ¼ bare-metal stent(s); SES ¼ sirolimus-eluting stent(s).
Figure 2. Five-Year Time-to-Event Curves for the Primary Endpoint of
Cardiac Death, MI, or Clinically Indicated TVR
Cumulative incidence for 5 years with Kaplan-Meier yearly event rates (A) and
landmark analyses (0 to 1 and 1 to 5 years) (B) are shown. CI ¼ conﬁdence
interval; MI ¼ myocardial infarction; RR ¼ relative risk; TVR ¼ target vessel
revascularization; other abbreviations as in Figure 1.
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780angiographic and clinical ST according to the Academic
Research Consortium (ARC) (26) criteria, at 30 days,
6 months, 9 months, and 1 to 5 years. Timing of ST was
prespeciﬁed. The more comprehensive patient-oriented
clinical endpoint (POCE)da composite of all-cause death,
all MI, all-cause revascularizationdwas analyzed post hoc,
because this endpoint was recommended in the reporting
of stent-based clinical trials by the ARC (26) after com-
mencement of the LEADERS trial. An independent clinical
events committee, whose members were blinded to patients’
treatment allocation and trial results, independently adju-
dicated all deaths, potential MIs, ST, and revascularization
procedures. Patient safety was assessed at prespeciﬁed
intervals by an independent data monitoring committee.
Statistical analysis. The statistical analysis plan has previ-
ously been published (19,20). The LEADERS trial was
powered for noninferiority based on the primary endpoint at
9 months. The expected rate of the primary endpoint at
9 months was 8% in both treatment arms. Noninferiority
would be declared if the upper limit of the 1-sided 95%
conﬁdence interval (CI) of the absolute risk difference was
not >4%. Eight hundred ﬁfty patients per group were
required to yield >90% power to detect noninferiority at
a 1-sided type 1 error of 0.05. After noninferiority was
established, regular 2-sided 95% CIs and 2-sided p values
were used to allow conventional interpretation of results
(as for a superiority design). Continuous variables are pre-
sented as mean  SD, and categorical data as counts
and percentages. Patients were analyzed on an intention-to-treat basis. The Mantel-Cox method was used to calculate
rate ratios (RR) and 95% CIs for comparisons of clinical
outcomes between groups, and the log-rank test was used to
calculate corresponding p values. Time-to-event variables are
presented as Kaplan-Meier (KM) curves, and incidences
compared using the log-rank test. Corrected KM curves for
clinical outcomes were constructed by removing the
ST-adjudicated clinical event from the KM curves. The ST-
adjudicated clinical event was associated with deﬁnite ST if
it occurred within a 1-day window (before or after the
adjudicated ST event). This methodology was in line with
that previously described (27). Corrected KM curves allowed
for direct comparisons of both study devices using all ARC
deﬁnitions of ST, including the more sensitive, but less
speciﬁc, deﬁnition of possible ST (unexplained death
beyond 30 days) (28). Stratiﬁed analyses were performed as
previously reported (19,20). A chi-square test was used to
assess interaction between treatment effect and baseline
clinical or angiographic characteristics. Landmark analyses
were performed as previously reported (20), using a land-
mark point of 1 year and between 1 and 5 years. Landmark
Table 2. Stratiﬁed Analysis of the Primary Endpoint at 5 Years in Patients Randomly Assigned to Implantation With the Biodegradable Polymer BES
or Durable Polymer SES
Biodegradable
Polymer BES
Durable
Polymer SES
Risk Ratio
(95% CI) p Value pinteraction*
Overall 186 (21.7) 216 (25.4) 0.83 (0.68–1.02)
.25 .5 1 2 4
Favors biodegradable
polymer BES
Favors durable
polymer SES
0.069
Diabetes mellitus 0.017
Yes 79 (35.4) 60 (31.4) 1.14 (0.81–1.60) 0.44
No 107 (16.9) 156 (23.7) 0.69 (0.54–0.88) 0.003
ACS 0.31
Yes 93 (19.8) 120 (25.4) 0.76 (0.58–0.99) 0.043
No 93 (24.0) 96 (25.5) 0.93 (0.70–1.24) 0.61
STEMI 0.032
Yes 17 (12.6) 35 (25.0) 0.46 (0.26–0.83) 0.008
No 169 (23.4) 181 (25.5) 0.91 (0.73–1.12) 0.36
SYNTAX scorey 0.41
High (12) 81 (22.1) 104 (29.6) 0.71 (0.53–0.95) 0.020
Low (<12) 54 (16.0) 63 (18.4) 0.86 (0.60–1.24) 0.43
LAD involvement 0.91
Yes 83 (20.4) 99 (23.7) 0.84 (0.63–1.13) 0.25
No 103 (22.9) 117 (27.1) 0.82 (0.63–1.07) 0.15
Multivessel disease 0.48
Yes 49 (23.4) 54 (30.7) 0.73 (0.50–1.08) 0.12
No 137 (21.1) 162 (24.0) 0.86 (0.69–1.08) 0.21
De novo lesions 0.82
Yes 165 (20.9) 188 (24.3) 0.84 (0.68–1.04) 0.12
No 21 (30.9) 28 (37.8) 0.79 (0.45–1.39) 0.41
Small-vessel disease 0.56
Yes 135 (23.1) 150 (26.4) 0.86 (0.68–1.09) 0.22
No 51 (18.8) 66 (23.6) 0.76 (0.53–1.10) 0.14
Long lesions 0.48
Yes 62 (23.7) 69 (30.7) 0.74 (0.53–1.05) 0.093
No 124 (20.9) 147 (23.6) 0.87 (0.68–1.10) 0.24
Values are n (%). The primary endpoint consists of cardiac death, MI, or clinically indicated target vessel revascularization. *Interaction is for risk ratio 0 to 1 year and risk ratio 1 to 4 years for biodegradable
polymer BES and durable polymer SES. ySYNTAX score separated by the median into low (<12) and high (12) SYNTAX scores.
ACS ¼ acute coronary syndrome; CI ¼ conﬁdence interval; LAD ¼ left anterior descending artery; MI ¼myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction; other abbreviations as
in Table 1.
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781analyses were done overall, and after stratiﬁcation of
clinical events according to their association with deﬁnite
ST. An interaction between treatment effect and time
(ﬁrst year vs. subsequent years) was performed. All statis-
tical analyses were performed using the SAS System
version 9 or higher software (SAS Institute, Cary, North
Carolina).
Results
Figure 1 shows the trial proﬁle at completion of the
LEADERS trial at 5 years. In total, 1,707 patients with
2,472 lesions were randomized to undergo implantation
with biodegradable polymer BES (n ¼ 857, 1,257 lesions) or
durable polymer SES (n ¼ 850, 1,215 lesions). At 5 years,follow-up data were available in 825 of 857 (96%) patients
in the biodegradable polymer BES arm, and 809 of 850
(95%) in the durable polymer SES arm. Baseline charac-
teristics have previously been described (19). The mean age
of patients was 64.6  10.8 versus 64.5  10.7 years in the
BES and SES arms, respectively. Almost a quarter of the
population had diabetes (26% vs. 22.5%), requiring insulin
in almost 10% (9.5% vs. 9.1%). ACS accounted for almost
one-half the population (54.8% vs. 55.7%), with ST-
segment elevation ACS in 15.8% vs. 16.5% in the BES and
SES arms, respectively.
Patient compliance with aspirin and dual antiplatelet
therapy was comparable between both treatment arms at 1,
2, 3, 4, and 5 years (Table 1). At 5 years, aspirin use alone
was high (664 of 724 [92%] vs. 644 of 696 [93%], p ¼ 0.57),
Figure 3. The 5-Year Time-to-Event Curves for the POCE
Patient-oriented composite events (POCE) is a composite of all-cause death,
all MI, and all-cause revascularization. Kaplan-Meier yearly event rates are
shown. Abbreviations as in Figures 1 and 2.
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782and dual antiplatelet therapy was used in a minority of
patients (92 of 724 [13%] vs. 97 of 696 [14%], p ¼ 0.50)
in the BES and SES arms, respectively.
Primary endpoint. At 5 years, the biodegradable polymer
BES was noninferior to durable polymer SES for the primary
endpointda composite of cardiac death, MI, and clinically
indicated TVR: 186 (22.3%) versus 216 (26.1%), rate ratio
(RR): 0.83 (95% CI: 0.68 to 1.02), p for noninferiority
<0.0001 (Fig. 2A). A trend toward superiority for the
biodegradable polymer BES, compared with the durable
polymer SES, was apparent (p for superiority ¼ 0.069). At
approximately 6 months, the KM curves began to continually
diverge for the primary endpoint in favor of the biodegradable
polymer BES up to 5 years. A test for interaction between
treatment effect and time (0 to 1 and 1 to 5 years) was
negative (pinteraction ¼ 0.60) (Fig. 2B). Outcomes related to
components of the primary endpoint are enclosed in the
Online Appendix.
The ﬁndings for the primary endpoint were consistent
across the stratiﬁed analyses for different patient subgroups,
including ACS and more anatomically complex coronary
artery disease (by lesion subset types and the SYNTAX score)
(Table 2), with the exception of diabetes and ST-segment
elevation MI (STEMI). In nondiabetic patients, the biode-
gradable BES outperformed the durable polymer SES
for the primary endpoint at 5 years, whereas the primary
endpoint between devices in diabetic patients was (interaction
p value ¼ 0.017). In STEMI, the biodegradable BES out-
performed the durable polymer SES for the primary endpoint
at 5 years (interaction p value ¼ 0.032).
Patient-oriented composite endpoint. At 5 years, the
biodegradable polymer BES was superior to the durable
polymer SES for the more comprehensive POCEda
composite of all-cause death, MI, and all-cause revascular-
ization: 297 (35.1%) versus 339 (40.4%), RR: 0.84 (95% CI:
0.71 to 0.98), p for superiority ¼ 0.023 (Fig. 3). Further
analyses indicated the reduction in POCE was predomi-
nantly secondary to a reduction in all-cause revasculariza-
tion: 206 (24.0%) versus 241 (28.4%), RR: 0.81 (95% CI:
0.67 to 0.98) in the BES and SES arms, respectively.
Stent thrombosis. Table 3 details the incidence of ST,
according to the ARC (26) deﬁnition at 5 years. For deﬁnite
ST at 5 years, a trend toward signiﬁcance for a reduction in
incidence was seen for the biodegradable polymer BES
compared with the durable polymer SES (22 [2.6%] patients
versus 36 [4.5%], RR: 0.60 [95% CI: 0.35 to 1.02], p for
superiority ¼ 0.057) (Fig. 4A). Landmark analysis de-
monstrated that there was a signiﬁcant interaction between
treatment effect and time (0 to 1 years, and 1 to 5 years,
interaction p value ¼ 0.022) (Fig. 4B). Namely, there was
a signiﬁcantly lower risk of deﬁnite ST for the biodegradable
polymer BES compared with the durable polymer SES,
from years 1 to 5 (RR: 0.26 [95% CI: 0.10 to 0.68];
p¼ 0.003), whereas at years 0 to 1, incidences of deﬁnite STwere (RR: 0.99 [95% CI: 0.51 to 1.95]; p ¼ 0.98). Similar
ﬁndings were shown for deﬁnite/probable ST (years 0 to 1:
RR: 1.20 [95% CI: 0.65 to 2.21]; p¼ 0.55; years 1 to 5: RR:
0.31 [95% CI: 0.14 to 0.69]; p ¼ 0.002; pinteraction ¼ 0.007)
(Online Appendix).
Landmark analyses of clinical outcomes stratiﬁed
according to their association with deﬁnite ST indicated
a signiﬁcant interaction between treatment effect and time
(0 to 1 and 1 to 5 years) (Table 4). Speciﬁcally, there were
more favorable clinical outcomes for the biodegradable
polymer BES compared with the durable polymer SES in
years 1 to 5 (but not in years 0 to 1) for the primary endpoint
(cardiac death, MI, clinically indicated TVR) (interaction
p value ¼ 0.035) and POCE (all-cause death, MI, all-cause
revascularization) (interaction p value ¼ 0.033). Further
analyses indicated that the ST-associated clinical outcomes
were largely secondary to a reduction in MI or clinically
indicated TVR (interaction p value ¼ 0.035), but not cardiac
mortality (interaction p value ¼ 0.99). Corrected KM curves
for the primary endpoint and its components, with the
ST-associated clinical events removed, corroborated these
ﬁndings (Fig. 5), with reductions in mortality with either
device.
SYNTAX score. SYNTAX scores were available in 1,397 of
1,707 patients (82%). Prior coronary artery bypass graft
surgery occurred in 197 of 1,707 patients (11.5%) precluding
SYNTAX score assessments. The median SYNTAX score
was 12.0 (interquartile range: 7.0 to 19.0). Table 5 illustrates
the 5-year clinical outcomes stratiﬁed by the complexity of
coronary artery disease, as deﬁned by the median SYNTAX
score, into low (<12 [median]; n ¼ 337 [BES], 343 [SES],
680 [in total]) and high (12 [median]; n ¼ 366 [BES],
351 [SES], 717 [in total]) anatomically complex groups.
Table 3. ST According to the ARC Criteria (26) at 5 Years
Clinical Outcome
Biodegradable Polymer BES
(n ¼ 857)
Durable Polymer SES
(n ¼ 850)
Risk Ratio
(95% CI) p Value pinteraction*
Deﬁnite ST 22 (2.6) 36 (4.2) 0.60 (0.35 to 1.02) 0.057
Early (1 month) 14 (1.6) 14 (1.6) 0.99 (0.47 to 2.08) 0.98 0.022
Late (>1 month to 1 yr) 3 (0.4) 4 (0.5) 0.74 (0.17 to 3.33) 0.70
Very late (>1 yr) 5 (0.6) 19 (2.2) 0.26 (0.10 to 0.69) 0.0034
Overall 22 (2.6) 36 (4.2)y 0.60 (0.35 to 1.02) 0.057
Probable ST 10 (1.2) 8 (0.9) 1.23 (0.49 to 3.11) 0.66
Early (1 month) 5 (0.6) 2 (0.2) 2.48 (0.48 to 12.78) 0.26 0.056
Late (>1 month to 1 yr) 2 (0.2) 0 (0.0) 4.97 (0.24 to 103.4) 0.16
Very late (>1 yr) 3 (0.4) 6 (0.7) 0.49 (0.12 to 1.95) 0.30
Overall 10 (1.2) 8 (0.9) 1.23 (0.49 to 3.11) 0.66
Deﬁnite/probable ST 31 (3.6) 44 (5.2) 0.69 (0.44 to 1.10) 0.12
Early (1 month) 18 (2.1) 16 (1.9) 1.12 (0.57 to 2.19) 0.75 0.007
Late (>1 month to 1 yr) 5 (0.6) 4 (0.5) 1.24 (0.33 to 4.63) 0.75
Very late (>1 yr) 8 (0.9) 25 (2.9) 0.31 (0.14 to 0.69) 0.0024
Overall 31 (3.6) 44 (5.2) 0.69 (0.44 to 1.10) 0.12
Possible ST 47 (5.5) 45 (5.3) 1.02 (0.68 to 1.54) 0.91
Early (1 month) d d d d 0.54
Late (>1 month to 1 yr) 7 (0.8) 9 (1.1) 0.77 (0.29 to 2.08) 0.61
Very late (>1 yr) 40 (4.7) 36 (4.2) 1.09 (0.69 to 1.71) 0.72
Overall 47 (5.5) 45 (5.3)y 1.02 (0.68 to 1.54) 0.91
Values are n (%). *p Values for interaction between risk ratio and time (0 to 1 year and 1 to 5 years). yExcludes 1 deﬁnite stent thrombosis (ST)
occurring after 60 days in the same patient who had an early ST at 3 days.
ARC ¼ Academic Research Consortium; other abbreviations as in Tables 1 and 2.
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783In more anatomically complex coronary artery disease
(SYNTAX score 12), the biodegradable polymer BES
(compared with the durable polymer SES) demonstrated
a trend toward reduction in the incidence of deﬁnite ST
(interaction p value ¼ 0.051) (Fig. 6) and POCE (interac-
tion p value ¼ 0.073).
Discussion
The main ﬁndings of this study are that at 5 years: 1) the
biodegradable polymer BES was noninferior to the durable
polymer SES based on the primary endpoint; 2) the ﬁnd-
ings for the primary endpoint were consistent across
different patient subgroups, with the exception of diabetes
(primary endpoint between devices) and STEMI (biode-
gradable polymer BES outperformed the durable polymer
SES for the primary endpoint); 3) the more comprehensive
POCE (all-cause death, all MI, and all-cause revasculari-
zation) indicated the biodegradable polymer BES to be
superior to the durable polymer SES; 4) the biodegradable
polymer BES was associated with a signiﬁcant reduction in
very late (>1 year) deﬁnite ST, which corresponded to
a signiﬁcant reduction in ST-associated clinical events
(primary endpoint); 5) the very late ST-associated clinical
events primarily consisted of a reduction in MI and all-
cause revascularization, with minimal impact on long-termmortality; and 6) the biodegradable polymer BES appeared
to outperform the durable polymer SES in more anatomi-
cally complex coronary artery disease, leading to reductions
in deﬁnite ST and associated clinical events.
All-comers ischemic endpoint analysis. The present study
highlights the noninferiority of the biodegradable polymer
BES compared with the durable polymer SES and,
although not powered for superiority, demonstrated a trend
toward clinical superiority (p ¼ 0.069) (Fig. 2A). In addi-
tion, the ﬁndings of the study of a signiﬁcant reduction in
the more robust and unequivocal POCE of all-cause death,
all MI, or all-cause revascularization, in subjects implanted
with biodegradable polymer BES, lends further support to
its increased safety compared with the durable polymer
SES.
The other most notable ﬁnding of the study was the
increased safety of the biodegradable polymer BES,
compared with the durable polymer SES, secondary to
a signiﬁcant reduction in very late (>1 year) ST and its
associated clinical outcomes. A ﬁnding that continued out to
5 years, with the curves continuing to separate (Fig. 4). In
addition, the incidence of ST associated with the biode-
gradable polymer BES appeared to have almost plateaued.
Despite the ﬁndings of improved safety with the biode-
gradable polymer BES, further analyses indicated that there
was no signiﬁcant effect on mortality, even if all the
Figure 4. The 5-Year Time-to-Event Analyses for Deﬁnite ST
Cumulative incidence for 5 years (A) and landmark analyses (0 to 1 and 1 to
5 years) (B) are shown. ST ¼ stent thrombosis; other abbreviations as in
Figures 1 and 2.
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784deﬁnitions by ARC criteria (26) for ST were used, including
the least stringent of deﬁnitions (i.e., possible ST: unex-
plained death beyond 30 days) (Fig. 5). The advantage of
the present study is that a direct comparison of both stents
was possible in a randomized setting, using all the ARC
criteria, and showed that the reduction in deﬁnite ST
clinical events, related to the biodegradable polymer BES,
were predominantly secondary to a reduction in MI and
clinically indicated TVR. Although we cannot exclude the
likelihood that the data were underpowered to associate
deﬁnite late ST with mortality, the complete lack of any
association with mortality in the present study may be
plausible for reasons explained in the following text.
First, different pathophysiological mechanisms (29) have
been linked to early ST (<30 days) (i.e., procedure-related
complications or impaired platelet reactivity) (30,31) and
late ST (30 days to 1 year)/very late ST (>1 year) (i.e.,
impaired re-endothelialization, hypersensitivity reaction to
the durable polymer, stent malapposition or fracture, and
neoatherosclerosis) (9,15,32–34). Accordingly, patients with
early ST were more likely to present with thrombotic oc-
clusion of the culprit vessel, and therefore, were at a higherrisk of sudden death, perhaps in part due to a lack of
instantly recruited collaterals, which would conceivably be
more evident in patients with more advanced coronary artery
disease (29,35,36). Conversely, patients with late (30 days to
1 year) or very late (>1 year) ST were more likely to have
Thrombolysis In Myocardial Infarction ﬂow grade 2 or 3 at
initial angiography on presentation, and therefore, more
likely to present with a MI or repeat revascularization, and
less likely to present with sudden death, as reported in
2 recent large registry studies (37,38). Notably, in both
registries, there remained an association of mortality with
very late ST, albeit at a substantially reduced incidence
compared to early ST (37,38).
Second, 2 recent studies examining pooled analyses of
contemporary stent trials demonstrated stent generation to
have little impact onmortality, despite proven reductions in ST
with the newer-generationDES thatwere investigated (39,40).
SYNTAX score and diabetes. The present study demon-
strated that in more anatomically complex coronary artery
disease, the biodegradable polymer BES potentially out-
performed the durable polymer SES in terms of reductions
in deﬁnite ST (interaction p ¼ 0.051) and POCE (inter-
action p ¼ 0.073) (Table 2). Delayed arterial healing has
been associated with bifurcation stenting, overlapping stents,
stent underexpansiondall of which are associated with
higher SYNTAX scoresdand causally linked to late and
very late ST with ﬁrst-generation DES (32,33). As shown in
the present study, ST was associated with reductions in
associated clinical outcomes at 5 years, extending the
previously reported clinical beneﬁt of biodegradable polymer
BES, compared with durable polymer SES, in higher
SYNTAX scores, previously reported at 3 years (21).
Conversely, on stratiﬁed analyses, the biodegradable
polymer BES appeared to show no beneﬁt in diabetic
patients, compared with the durable polymer SES, in
terms of reduction in the primary endpoint (interaction
p ¼ 0.017). The reasons for the apparent lack of beneﬁt of
the biodegradable polymer BES, compared with durable
polymer SES, in diabetic patients is unclear. As to whether
this is related to chance or other factors is speculative.
Notably, it has recently been shown that the outcomes
for patients with diabetes after PCI may be more favorable,
if end-organ manifestations of diabetes are not yet
present, such as chronic kidney disease (40–44). Further,
prospective studies are required to best understand these
hypothesis-generating concepts.
ST-segment elevation MI. In subjects presenting with
STEMI, the biodegradable BES was potentially associated
with a reduction in the primary endpoint compared with
the durable polymer SES (interaction p ¼ 0.032). A recent
meta-analysis of 15 randomized controlled trials comparing
ﬁrst-generation DES with BMS in patients with STEMI
(45), demonstrated that although there was an early beneﬁt
of DES in reducing repeat revascularization, this was
Table 4. Landmark Analyses of the Primary Endpoint and POCE According to the Association With Deﬁnite ST
Clinical Outcome
Biodegradable
Polymer BES
Durable
Polymer SES Risk Ratio (95% CI) p value pinteraction*
Not ST associated
.1 .2 .5 1 2 4 6
Favors biodegradable
polymer BES
Favors durable
polymer SES
Primary endpointy 0.99
0 to 1 yr 78/857 88/850 0.88 (0.64–1.19) 0.39
1 to 5 yrs 92/749 100/738 0.88 (0.66–1.16) 0.36
Cardiac death or MI 0.71
0 to 1 yr 48/857 48/850 0.99 (0.67–1.49) 0.98
1 to 5 yrs 63/779 68/781 0.90 (0.64–1.27) 0.55
Cardiac death 0.47
0 to 1 yr 18/857 23/850 0.78 (0.42–1.44) 0.42
1 to 5 yrs 47/817 45/814 1.02 (0.68–1.54) 0.92
MI 0.20
0 to 1 yr 39/857 29/850 1.34 (0.82–2.18) 0.23
1 to 5 yrs 27/779 31/781 0.85 (0.51–1.42) 0.53
Clinically indicated TVR 0.65
0 to 1 yr 37/857 46/850 0.79 (0.51–1.22) 0.28
1 to 5 yrs 51/776 54/760 0.90 (0.61–1.32) 0.59
MI or clinically indicated TVR 0.73
0 to 1 yr 70/857 71/850 0.98 (0.70–1.36) 0.88
1 to 5 yrs 62/749 66/738 0.90 (0.63–1.27) 0.53
POCEz 0.76
0 to 1 yr 143/857 168/850 0.83 (0.66–1.04) 0.10
1 to 5 yrs 136/689 145/662 0.87 (0.69–1.10) 0.25
ST associated
Primary endpointy 0.035
0 to 1 yr 13/857 14/850 0.92 (0.43–1.96) 0.83
1 to 5 yrs 3/749 14/738 0.20 (0.06–0.71) 0.005
Cardiac death or MI 0.086
0 to 1 yr 11/857 10/850 1.10 (0.46–2.58) 0.84
1 to 5 yrs 5/779 14/781 0.35 (0.13–0.96) 0.033
Cardiac death 0.99
0 to 1 yr 0/857 0/850 0.99 (0.02–49.9)
1 to 5 yrs 1/817 1/814 0.97 (0.06–15.4) 0.98
MI 0.086
0 to 1 yr 11/857 10/850 1.10 (0.46–2.58) 0.84
1 to 5 yrs 5/779 14/781 0.35 (0.13–0.96) 0.033
Clinically indicated TVR 0.12
0 to 1 yr 13/857 14/850 0.92 (0.43–1.95) 0.82
1 to 5 yrs 3/776 10/760 0.29 (0.08–1.04) 0.042
MI or clinically indicated TVR 0.035
0 to 1 yr 13/857 14/850 0.92 (0.43–1.96) 0.83
1 to 5 yrs 3/749 14/738 0.20 (0.06–0.71) 0.005
POCEz 0.033
0 to 1 yr 15/857 14/850 1.06 (0.51–2.20) 0.88
1 to 5 yrs 3/689 12/662 0.23 (0.07–0.82) 0.013
Values are n/total n (%). *Interaction is for risk ratio 0 to 1 year and risk ratio 1 to 5 years. yPrimary endpoint: cardiac death, MI, clinically indicated target vessel revascularization (TVR). zPOCE: patient-
oriented composite endpoint (all-cause death, MI, all-cause revascularization).
Abbreviations as in Table 1.
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Figure 5. Corrected Kaplan-Meier Curves for Deﬁnite, Probable, and Possible ST, Comparing the Polymer and Polymer
Kaplan-Meier (KM) estimates of cardiac death (black lines), cardiac death or myocardial infarction (MI) (green lines), and the primary endpoint (cardiac death, MI, or
clinically indicated TVR), according to ARC (26) deﬁnition. Broken lines indicate corrected KM curves after the exclusion of the stent thrombosis (ST)-related clinical
event. Deﬁnite, probable, and possible ST are respectively superimposed on the Kaplan-Meier curves as a circle, square, and triangle. If all the ST-related events had
been eliminated, the reduction in the primary endpoint, and cardiac death or MI, was lower with the biodegradable polymer BES compared with the durable polymer
SES. Notably, cardiac mortality was not associated with ST using all ARC deﬁnitions (deﬁnite, probable, possible), with a reduction in mortality with either device. ARC ¼
Academic Research Consortium; other abbreviations as in Figures 1, 2, and 4.
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786offset by a 2-fold increased risk of very late (>1 year) ST.
Mechanisms have been linked to penetration of stent struts
into thrombus and necrotic core, with resultant delayed
arterial healing (46). More recently, the COMFORTABLE
Acute MI (Comparison of Biolimus Eluted From an
Erodible Stent Coating With Bare Metal Stents in Acute
ST-Elevation Myocardial Infarction) randomized, multi-
center trial (47,48) demonstrated the superiority of a biode-
gradable polymer BES to BMS with the identical metallic
platform, in terms of a signiﬁcant reduction in the primary
endpoint of MACE (BES: 4.3% vs. BMS: 8.7%, p ¼ 0.004)
and the more robust POCE (all-cause death, any MI, and
all-cause revascularization) (BES: 8.4% vs. BMS: 12.2%;
p ¼ 0.04) at 1 year. At 1 year, numerically lower deﬁnite ST
was also seen (BES: 0.9% vs. BMS: 2.1%; p ¼ 0.10). In
the randomized EXAMINATION (Clinical Evaluation of
the Xience-V Stent in Acute Myocardial Infarction) trial
(49) comparing the newer-generation durable polymer
everolimus-eluting stent (with BMS in patients with
STEMI, the primary endpoint of POCE was similar in both
treatment arms (11.9% vs. 14.2%; p ¼0.19). The incidence
of target vessel revascularization (3.7% vs. 6.8%; p ¼ 0.0077)
and deﬁnite ST (0.5% vs. 1.9%; p ¼ 0.019) were, however,
signiﬁcantly reduced at 1 year with the durable polymer
everolimus-eluting stent compared with BMS. Longer-term
follow-up of both trials are awaited to fully understand thelong-term impact of durable and biodegradable polymer
newer-generation DES on very late ST and its associated
clinical impact (47–49).
Study limitations. The main limitations of this study are that
the trial was located in high-volume centers in Europe alone.
We therefore cannot exclude geographical variations in PCI
practice outside of Europe, or in lower-volume centers.
Analyses based on the SYNTAX score represent a post hoc
analysis of the data and should be viewed as hypothesis
generating. The incomplete data of the SYNTAX score
analyses may have affected the results, but because this
occurred at random(50), in aminority of patients (113 of 1,707
[6.6%]), the effect of this should have been minimal. Because
the trial was not sufﬁciently powered for ST,we cannot exclude
the possibility that the ﬁndings related to ST are secondary to
chance.However, ST according to the deﬁnitions ofARC (26)
was a prespeciﬁed endpoint, all ST events were adjudicated
independently by a masked clinical events committee accord-
ing to established criteria, and the incidence of deﬁnite ST
continued to diverge between the 2 investigated devices up to 5
years, which would make the play of chance unlikely.
Conclusions
Biodegradable polymer–based BES are noninferior to durable
polymer SES. Compared with durable polymer SES, the
Table 5. Association of 5-Year Clinical Outcomes Stratiﬁed by the Complexity of Coronary Artery Disease
Clinical Outcome
Biodegradable
Polymer BES
Durable
Polymer SES
Risk Ratio
(95% CI) p Value pinteraction*
Primary endpointy
.25 .5 1 2 4
Favors durable 
polymer SES
Favors biodegradable
polymer BES
0.41
High SYNTAX score 81 (22.1) 104 (29.6) 0.71 (0.53–0.95) 0.020
Low SYNTAX score 54 (16.0) 63 (18.4) 0.86 (0.60–1.24) 0.43
Cardiac death 0.24
High SYNTAX score 27 (7.4) 38 (10.8) 0.66 (0.40–1.09) 0.10
Low SYNTAX score 19 (5.6) 18 (5.2) 1.08 (0.57–2.06) 0.81
MI 0.54
High SYNTAX score 37 (10.1) 34 (9.7) 1.03 (0.64–1.64) 0.90
Low SYNTAX score 22 (6.5) 27 (7.9) 0.82 (0.46–1.44) 0.49
Clinically indicated TVR 0.14
High SYNTAX score 44 (12.0) 63 (17.9) 0.62 (0.42–0.92) 0.015
Low SYNTAX score 32 (9.5) 33 (9.6) 0.99 (0.61–1.62) 0.98
POCEz 0.073
High SYNTAX score 133 (36.3) 167 (47.6) 0.70 (0.56–0.88) 0.002
Low SYNTAX score 94 (27.9) 97 (28.3) 0.98 (0.73–1.30) 0.87
Deﬁnite ST 0.051
High SYNTAX score 9 (2.5) 22 (6.3) 0.38 (0.18–0.83) 0.011
Low SYNTAX score 8 (2.4) 6 (1.7) 1.37 (0.47–3.95) 0.56
Values are n (%). Coronary artery disease complexity is separated by the SYNTAX score into low (<12 [median]; n ¼ 337 [BES], 343 [SES], 680 [in total]) and high (12 [median]; n ¼ 366 [BES], 351 [SES], 717
[in total]) anatomically complex groups. *Interaction is for risk ratio High SYNTAX Score and risk ratio Low SYNTAX Score. yPrimary endpoint: cardiac death, MI, clinically indicated TVR. zPOCE: all-cause
death, MI, all-cause revascularization.
Abbreviations as in Tables 1 and 4.
Figure 6. The 5-Year Time-to-Event Analyses for Deﬁnite ST Stratiﬁed by Complexity of Coronary Artery Disease
Five-year time-to-event analyses stratiﬁed by a low (<12) and high (12) SYNTAX score. Biodegradable polymer BES was associated with a signiﬁcant reduction in
deﬁnite ST in the high SYNTAX scores (12) compared with durable polymer SES. Abbreviations as in Figures 1 and 4.
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788biodegradable polymer–based BESwas related to a signiﬁcant
reduction in very late (>1 year) ST and associated composite
clinical endpoints. The safety beneﬁt of the biodegradable
polymer–based BES appeared to occur in predominantly
more complex coronary artery disease, subjects presenting
with a STEMI, and patients without diabetes, and was
secondary to a reduction in MI and repeat revascularization.
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